Publications

Critical Reviews in Oncology / Hematology

Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

Lorenzo Gerratana, Qiang Zhang, Ami Naimish Shah, Andrew, Adam Davis, Youbin Zhang, Firas Wehbe, Wenan Qiang, Lisa Flaum, Brian Steven Finkelman, William John Gradishar, Leonidas C. Platanias, Amir Behdad, Massimo Cristofanilli

January  2020

Read More

BREAST CANCER RESEARCH

Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

Davis, A.A., Zhang, Q., Gerratana, L. et al.

December  2019

Read More

Abstracts

2019 SABCS

Characterization of metastatic breast cancer through a novel next generation sequencing platform for hypothesis generation on endocrine resistance

Lorenzo Gerratana, Qiang Zhang, Andrew A Davis, Ami N Shah, Jianjun Yu, Shidong Jia, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradisha, and Massimo Cristofanilli

December 2019

Read More

2019 SABCS

Blood-based detection of PTEN loss and pathway alterations for personalized treatment of breast cancer

Pan Du, Eric Jia and Zhixin Zhao

December 2019

Read More

2019 SABCS

Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA Bookmark

Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli

December 2019

Read More

2019 ASCO

Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival

Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee

June 2019

Read More

2019 AACR

Prognostic and predictive utility of copy number variations (CNVs) in circulating tumor DNA (ctDNA) from metastatic castration-resistant prostate cancer (mCRPC) patients

Heidi Fettke, Edmond M. Kwan, Jianjun Yu, Amy Wang, Carlos Montesinos, Calvin Wong, Xue Gong, Tiantian Zheng, Peter Pan Du, Shidong Jia, Andrew Mant, Phillip Parente, Carmel Pezaro, Arun A. Azad

April 2019

Read More

2019 AACR

Combined immunohistochemistry and NGS-based patient profiling for predicting anti-PD-1/PD-L1 therapy response

Jianjun Yu, Jianguo Dong, Amy Wang, Joseph S. Krueger

April 2019

Read More

2019 AACR

Development and validation of PredicineATLAS, a 600-gene liquid biopsy panel for simultaneous detection of TMB and genomic alterations in immuno-oncology

Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du

April 2019

Read More

2019 ASCO-GU

Plasma cell-free DNA-based prognosis in metastatic hormone sensitive prostate cancer

Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu

February 2019

Read More

2019 ASCO-GU

Plasma-based exploratory biomarker analysis to evaluate GT0918 in a phase I/II study in mCRPC patients

Jianjun Yu, Amy Wang, Zhixin Zhao, Shidong Jia, Phoebe Zhang, Karl Zhou

February 2019

Read More

2018 SABCS

Molecular characterization of circulating tumor DNA in Chinese metastatic breast cancer (mBC) patients

Yu J, Li H, Zhang S, Wang A, Zhao Z

December 2018

Read More

Annals of Oncology

Circulating tumor DNA and RNA as an exploratory biomarker to evaluate GT0918 in a phase I/II clinical trial in mCRPC patients

M Tan, S Zhang, Z Zhao, A Wang, D Cheung, P Du, J Yu, S Jia, C Guo, Y Tong. et al.

October 2018

Read More

Get in touch

Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.